This article is more than 5 years old. Information may no longer be current.

Avedro begins two new cross-linking trials in US

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Avedro announced that the first patients have been treated in two U.S. Food and Drug Administration clinical trials, according to a press release.

LASIK with cross-linking (LASIK Xtra) is a 2-minute procedure to investigate if cross-linking after LASIK reduces regression of refractive outcome in patients with hyperopia or hyperopic astigmatism, the release said.

Pulse accelerated cross-linking investigates pulsed UVA light to treat keratoconus, according to the release. Avedro’s KXL system allows for pulsed UVA light, which is important for higher-power accelerated cross-linking.
The KXL system is available internationally. No Avedro products have been approved for use in the U.S.